Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma Limited, received approval from the U.S. Federal Trade Commission on June 22, 2026 to proceed with its acquisition of Lannett Company LLC, a Pennsylvania-based generic pharmaceutical company, the company said in a regulatory filing.
The deal, valued at $250 million (approximately ₹2,357 crore, at current exchange rates of around ₹94.3 to the dollar) on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of June 2026.
Pennsylvania-based generics maker brings 4 billion-dose capacity
Lannett specialises in developing and commercialising a diversified portfolio of complex, non-opioid controlled substances. The acquisition will expand Aurobindo USA’s product offering in this segment and add a US-based manufacturing facility to its network.
Lannett’s manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, adding significantly to Aurobindo USA’s domestic manufacturing footprint. The company said this enhanced capacity aligns with US policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.
Deal seen as immediately accretive to earnings
The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share. Beyond near-term financial benefits, the company anticipates meaningful cost efficiencies, SG&A synergies, and operational integration advantages from the combination.
The acquisition will also add a differentiated pipeline of complex generics and controlled substances to Aurobindo’s portfolio, which the company said supports its sustainable long-term growth plans.
Aurobindo Pharma Limited is headquartered in Hyderabad and operates an integrated global pharmaceutical business spanning over 150 countries. The company runs more than 30 manufacturing and packaging facilities approved by regulators including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC and Brazil ANVISA. Its product portfolio covers seven major therapeutic areas including CNS, anti-retroviral, CVS, antibiotics, gastroenterological, anti-diabetic and anti-allergic segments, backed by an in-house R&D setup.
Aurobindo Pharma USA, Inc. focuses on developing, manufacturing and commercialising a broad range of generic and specialty pharmaceutical products in the US market. Lannett Company LLC, based in Pennsylvania, specialises in complex generic pharmaceutical products, including non-opioid controlled substances, and counts itself among the country’s oldest generic drugmakers.
Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, said, “This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.”
Tim Crew, Chief Executive Officer of Lannett Company, said, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment.”
